↓ Skip to main content

Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer

Overview of attention for article published in Cochrane database of systematic reviews, June 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

policy
1 policy source
twitter
16 tweeters
facebook
1 Facebook page
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
175 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer
Published in
Cochrane database of systematic reviews, June 2019
DOI 10.1002/14651858.cd003506.pub2
Pubmed ID
Authors

Frank Kunath, Katrin Jensen, Mariona Pinart, Andreas Kahlmeyer, Stefanie Schmidt, Carrie L Price, Verena Lieb, Philipp Dahm

Twitter Demographics

The data shown below were collected from the profiles of 16 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 175 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 175 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 21 12%
Other 15 9%
Student > Bachelor 15 9%
Student > Ph. D. Student 10 6%
Researcher 9 5%
Other 35 20%
Unknown 70 40%
Readers by discipline Count As %
Medicine and Dentistry 47 27%
Nursing and Health Professions 13 7%
Unspecified 8 5%
Biochemistry, Genetics and Molecular Biology 5 3%
Pharmacology, Toxicology and Pharmaceutical Science 5 3%
Other 20 11%
Unknown 77 44%

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2021.
All research outputs
#2,008,190
of 23,150,406 outputs
Outputs from Cochrane database of systematic reviews
#4,399
of 12,383 outputs
Outputs of similar age
#45,577
of 353,595 outputs
Outputs of similar age from Cochrane database of systematic reviews
#87
of 180 outputs
Altmetric has tracked 23,150,406 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,383 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 32.5. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,595 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 180 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.